FUNDAMENTALS · Fundamentals · AU Healthcare

Radiopharm Theranostics (RAD) Fundamentals 2026 — Revenue Analysis | SniperIQ

Radiopharm Theranostics (RAD) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$45M, trading at A$0.02 on the ASX. This SniperIQ fundamentals page covers Radiopharm Theranostics's valuation, profitability (net margin -364.0%), revenue (A

3M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA$45M
Net Margin-364.0%
Revenue (FY25)A
3M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Radiopharm Theranostics's market cap?

Radiopharm Theranostics (RAD) has a market capitalization of approximately A$45M, trading at A$0.02 on the ASX. Market cap moves with the live share price.

What is Radiopharm Theranostics's P/E ratio?

Radiopharm Theranostics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Radiopharm Theranostics?

Radiopharm Theranostics runs a net profit margin of -364.0%, a gross margin of 172.7%, and an operating margin of -402.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Radiopharm Theranostics generate?

Radiopharm Theranostics reported revenue of A

3M for fiscal year 2025, with net income of -A
7M and earnings per share (EPS) of -0.0176. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Radiopharm Theranostics pay a dividend?

Radiopharm Theranostics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Radiopharm Theranostics financially healthy?

Radiopharm Theranostics carries a debt-to-equity ratio of 0.00x and a current ratio of 3.01x, with a market beta of 0.80. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Radiopharm Theranostics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Radiopharm Theranostics (RAD) the key facts are: market cap A$45M, revenue A

3M, 52-week range 0.017-0.04. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Radiopharm Theranostics's full fundamentals live

Get Radiopharm Theranostics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Al-Razi Medical (9572) fundamentals · Baird Medical Investment Holdings (BDMD) fundamentals · Botanix Pharmaceuticals (BOT) fundamentals · Medical Developments International (MVP) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons